Evogene Ltd. (NASDAQ:EVGN – Get Rating)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.31 and traded as low as $0.72. Evogene shares last traded at $0.76, with a volume of 101,900 shares traded.
Separately, StockNews.com assumed coverage on shares of Evogene in a report on Thursday, March 31st. They issued a “sell” rating on the stock.
The company’s 50-day moving average price is $1.00 and its 200 day moving average price is $1.31. The stock has a market capitalization of $19.62 million, a PE ratio of -1.06 and a beta of 1.33.
Large investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in Evogene by 49.7% during the 1st quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 67,867 shares during the period. Virtu Financial LLC purchased a new position in Evogene during the 1st quarter valued at about $48,000. Vident Investment Advisory LLC lifted its position in Evogene by 68.5% during the 1st quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 34,082 shares during the period. Renaissance Technologies LLC lifted its position in Evogene by 51.8% during the 1st quarter. Renaissance Technologies LLC now owns 459,081 shares of the biotechnology company’s stock valued at $597,000 after acquiring an additional 156,716 shares during the period. Finally, Sigma Planning Corp lifted its position in Evogene by 88.0% during the 1st quarter. Sigma Planning Corp now owns 31,410 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 14,700 shares during the period.
Evogene Company Profile (NASDAQ:EVGN)
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements.
- Get a free copy of the StockNews.com research report on Evogene (EVGN)
- Dividend Stocks and Your Roth IRA
- The Analysts Upgrade… Retail Stocks?
- The Q2 Earnings Season Could Be A Bloodbath
- The Institutions Turn The Tide For Jabil
- Commercial Metals Company Is Ready To Rebound
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.